Moreover, the successful story of trofinetide (72, 73), an analogous IGF-1 small molecule that became the first drug to receive the FDA approval to improve sociability and cognition in a neurodevelopmental disorder (Rett syndrome), suggests that this drug could also be considered for the treatment of preterm newborns. The gene discussed is IGF1; the disease is atypical Rett syndrome.